scholarly journals P436 Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S298-S298
Author(s):  
M. Jimenez ◽  
M. Sierra-Ausin ◽  
N. Cano ◽  
P. Suarez ◽  
M. Fernandez-Gundin ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Inflammatory Bowel Diseases ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Secondary Loss ◽  
Loss Of Response ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases

2019 ◽  
Vol 85 (4) ◽  
pp. 722-728 ◽  
Author(s):  
Benjamin Nemoz ◽  
David Ternant ◽  
Sébastien Bailly ◽  
Elodie Gautier‐Veyret ◽  
Jean‐François Jourdil ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Inflammatory Bowel Diseases ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

2019 ◽  
Vol 17 (9) ◽  
pp. 1655-1668.e3 ◽  
Author(s):  
Konstantinos Papamichael ◽  
Adam S. Cheifetz ◽  
Gil Y. Melmed ◽  
Peter M. Irving ◽  
Niels Vande Casteele ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Inflammatory Bowel Diseases ◽  
Drug Monitoring ◽  
Biologic Agents ◽  
Therapeutic Drug ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response

2019 ◽  
Vol 14 (4) ◽  
pp. 542-556 ◽  
Author(s):  
Miles P Sparrow ◽  
Konstantinos Papamichael ◽  
Mark G Ward ◽  
Pauline Riviere ◽  
David Laharie ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Treatment Algorithm ◽  
Significant Proportion ◽  
Clinical Importance ◽  
Therapeutic Drug ◽  
Secondary Loss ◽  
Loss Of Response ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Abstract Biologic therapies have revolutionized the management of inflammatory bowel disease [IBD], but primary and secondary non-responses occur in a significant proportion of patients. Therapeutic drug monitoring [TDM] now has an established role in the treatment algorithm for managing secondary loss of response to anti-tumour necrosis factor [anti-TNF] agents during maintenance therapy. Data to support the use of TDM in the management of secondary loss of response to vedolizumab and ustekinumab are emerging. The potential to prevent primary non-response to biologic agents during induction is of equal, and potentially greater, clinical importance. Again, most data supporting the use of ‘proactive' TDM during induction pertains to the use of anti-TNF agents, but signals of efficacy for the use of TDM during induction with other biologic classes are now appearing. This review aims to summarize data on the use of TDM during induction to prevent pharmacokinetic primary non-response to all three classes of biologic therapy currently available for the treatment of IBD.

Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases

2015 ◽  
Vol 15 (8) ◽  
pp. 1107-1117 ◽  
Author(s):  
Carla Felice ◽  
Manuela Marzo ◽  
Daniela Pugliese ◽  
Alfredo Papa ◽  
Gian Lodovico Rapaccini ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Inflammatory Bowel Diseases ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Tnf Α ◽  
Bowel Diseases ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document